Kumar Prabhash
Homi Bhabha National Institute
627 Papers
860 Citations
Kumar Prabhash is an academic researcher from Homi Bhabha National Institute. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 32, co-authored 446 publications. Previous affiliations of Kumar Prabhash include Tata Memorial Hospital & AMIT.
Chat about Author
Papers
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon,Tudor Ciuleanu,Oscar Arrieta,Kumar Prabhash,Konstantinos N. Syrigos,Tuncay Göksel,Keunchil Park,Vera Gorbunova,Ruben Dario Kowalyszyn,Joanna Pikiel,Grzegorz Czyzewicz,Sergey Orlov,Conrad R. Lewanski,Michael Thomas,Paolo Bidoli,Shaker R. Dakhil,Steven J.M. Gans,Joo Hang Kim,Alexandru Grigorescu,Nina Karaseva,Martin Reck,Federico Cappuzzo,Ekaterine Alexandris,Andreas Sashegyi,Sergey Yurasov,Maurice Pérol +25 more
TL;DR: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC after platinum-based therapy and is registered with ClinicalTrials.gov.
1.2K
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Vanita Noronha,Vijay Patil,Amit Joshi,Nandini Menon,Anuradha Chougule,Abhishek Mahajan,Amit Janu,Nilendu Purandare,Rajesh Kumar,Sucheta More,Supriya Goud,Nandkumar Kadam,Nilesh Daware,Atanu Bhattacharjee,Srushti Shah,Akanksha Yadav,Vaishakhi Trivedi,Vichitra Behel,Amit Dutt,Shripad Banavali,Kumar Prabhash +20 more
TL;DR: Adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC.
394
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Giorgio V. Scagliotti,Vera Hirsh,Salvatore Siena,David H. Henry,Penella J. Woll,Christian Manegold,Philippe Solal-Celigny,Gladys Rodriguez,Maciej Krzakowski,Nilesh D. Mehta,Lara Lipton,José A. García-Sáenz,José Rodrigues Pereira,Kumar Prabhash,Tudor-Eliade Ciuleanu,Vladimir Kanarev,Huei Wang,Arun Balakumaran,Ira Jacobs +18 more
TL;DR: Survival data is presented for the subset of patients with lung cancer, participating in the phase 3 trial of denosumab versus zoledronic acid in the treatment of bone metastases from solid tumors (except breast or prostate) or multiple myeloma, as well as for overall survival among patients with non–small-cell lung cancer and SCLC.
330
Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial.
Tejpal Gupta,Jai Prakash Agarwal,Sandeep Jain,Reena Phurailatpam,Sadhana Kannan,Sarbani Ghosh-Laskar,Vedang Murthy,Ashwini Budrukkar,Ketayun A. Dinshaw,Kumar Prabhash,Pankaj Chaturvedi,Anil K. D'Cruz +11 more
TL;DR: IMRT significantly reduces the incidence and severity of xerostomia compared to 3D-CRT in curative-intent irradiation of head-neck squamous cell carcinoma of HNSCC.
307
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Vanita Noronha,Amit Joshi,Vijay Patil,Jai Prakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Vedang Murthy,Tejpal Gupta,Anil K. D'Cruz,Shripad Banavali,Prathamesh S. Pai,Pankaj Chaturvedi,Devendra Chaukar,Nikhil Pande,Arun Chandrasekharan,Vikas Talreja,Dilip Harindran Vallathol,Vijayalakshmi Mathrudev,Aparna Manjrekar,Kamesh Maske,Arati Sanjay Bhelekar,Kavita Nawale,Sadhana Kannan,Vikram Gota,Atanu Bhattacharjee,Shubhada Kane,Shashikant Juvekar,Kumar Prabhash +27 more
TL;DR: Once-every-3-weeks cisplatin at 100 mg/m2 resulted in superior LRC, albeit with more toxicity, than did once-a-week cisplinatin at 30 mg/ m2, and should remain the preferred chemoradiotherapy regimen for LAHNSCC in the adjuvant setting.
292